Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 75 years of age~* Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL~* Framingham risk score of 10% or less~* Fasting triglycerides \< 400 mg/dL~Exclusion Criteria:~* History of coronary heart disease~* New York Heart Association (NYHA) II - IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
- Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
- Ezetimibe (Type: ACTIVE_COMPARATOR): Participants received 10 mg ezetimibe orally once a day for 12 weeks.
- Evolocumab 70 mg Q2W (Type: EXPERIMENTAL): Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 105 mg Q2W (Type: EXPERIMENTAL): Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 140 mg Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 280 mg Q4W (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg Q4W (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg Q4W (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).